Search Results - "Turajlic, S."

Immunotherapy use outside clinical trial populations: never say never? by Rzeniewicz, K., Larkin, J., Menzies, A.M., Turajlic, S.

“…Based on favourable outcomes in clinical trials, immune checkpoint inhibitors (ICIs), most notably programmed cell death protein 1 (PD-1) and cytotoxic…”
Get full text

Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma by Spain, L., Higgins, R., Gopalakrishnan, K., Turajlic, S., Gore, M., Larkin, J.

“…Immune checkpoint inhibitors such as ipilimumab and nivolumab improve survival in patients with advanced melanoma and are increasingly available to clinicians…”
Get full text

Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature by Spain, L., Walls, G., Julve, M., O’Meara, K., Schmid, T., Kalaitzaki, E., Turajlic, S., Gore, M., Rees, J., Larkin, J.

“…Treatment with immune checkpoint inhibitors (ICPi) has greatly improved survival for patients with advanced melanoma in recent years. Anti-CTLA-4 and anti-PD1…”
Get full text

First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma by Turajlic, S., Gore, M., Larkin, J.

Get full text

Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review by Prelaj, A, Miskovic, V, Zanitti, M, Trovo, F, Genova, C, Viscardi, G, Rebuzzi, S E, Mazzeo, L, Provenzano, L, Kosta, S, Favali, M, Spagnoletti, A, Castelo-Branco, L, Dolezal, J, Pearson, A T, Lo Russo, G, Proto, C, Ganzinelli, M, Giani, C, Ambrosini, E, Turajlic, S, Au, L, Koopman, M, Delaloge, S, Kather, J N, de Braud, F, Garassino, M C, Pentheroudakis, G, Spencer, C, Pedrocchi, A L G

“…The widespread use of immune checkpoint inhibitors (ICIs) has revolutionised treatment of multiple cancer types. However, selecting patients who may benefit…”
Get more information

Representative sequencing: Profiling extreme tumor diversity by Litchfield, K., Au, L., Swanton, C., Turajlic, S.

Get full text

Representative sequencing: Profiling extreme tumor diversity by Litchfield, K., Swanton, C., Turajlic, S.

Get full text

Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond by Gerard, C., Shum, B., Nathan, P., Turajlic, S.

“…Uveal melanoma (UM) is the most common ocular malignancy in adults, associated with the poorest prognosis, with metastatic disease occurring in up to 50% of…”
Get full text

TCR sequencing: applications in immuno-oncology research by Sanromán, Á.F., Joshi, K., Au, L., Chain, B., Turajlic, S.

“…•T-cell receptor (TCR) interaction with major histocompatibility complex–antigen complexes leads to antitumour responses.•TCR sequencing analysis allows…”
Get full text

Severe cutaneous adverse reaction following COVID‐19 vaccination and immunotherapy: a second hit? by Hussain, K., Kawsar, A., Weir, J., Au, L., Turajlic, S., Larkin, J., Fearfield, L.

Get full text

WHO 2022 classification of penile and scrotal cancers: updates and evolution by Menon, S, Moch, H, Berney, DM, Cree, IA, Srigley, JR, Tsuzuki, T, Compérat, E, Hartmann, A, Netto, G, Rubin, MA, Gill, AJ, Turajlic, S, Tan, PH, Raspollini, MR, Tickoo, SK, Amin, M B

“…Squamous cell carcinoma (SCC) is the most common malignant tumour of the penis. The 2022 WHO classification reinforces the 2016 classification and…”
Get full text

Searching for the needle in the haystack: deconvoluting the evolutionary dynamics of residual disease in human glioblastoma by Shepherd, S.T.C., Litchfield, K., Turajlic, S.

Get full text

Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH by Siddiqui, M. S., Lai, Z. M., Spain, L., Greener, V., Turajlic, S., Larkin, J., Morganstein, D. L.

“…Purpose Ipilimumab, a monoclonal antibody inhibiting CLTA-4, is an established treatment in metastatic melanoma, either alone or in combination with nivolumab,…”
Get full text

Cutaneous toxicities in patients with melanoma receiving checkpoint inhibitor therapy: a retrospective review. The experience of a single large specialist institution by Edwards, C. L., Comito, F., Agraso Busto, S., Harland, C., Turajlic, S., Larkin, J., Heelan, K., Fearfield, L.

“…Summary Checkpoint inhibitor (CPI) therapy has significantly improved overall survival for metastatic melanoma, and is now approved for use in the adjuvant…”
Get full text

Academically led clinical trials: challenges and opportunities by Turajlic, S., Larkin, J., Swanton, C.

Get full text

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition by Turajlic, S., Furney, S.J., Stamp, G., Rana, S., Ricken, G., Oduko, Y., Saturno, G., Springer, C., Hayes, A., Gore, M., Larkin, J., Marais, R.

“…BRAF is mutated in ∼42% of human melanomas (COSMIC. http://www.sanger.ac.uk/genetics/CGP/cosmic/) and pharmacological BRAF inhibitors such as vemurafenib and…”
Get full text

Mechanism informs precision: In vivo determinants of response to anti-CTLA-4 antibodies by Furness, A.J.S., Arce Vargas, F., Litchfield, K., Rosenthal, R., Gore, M., Larkin, J., Turajlic, S., Swanton, C., Peggs, K., Quezada, S.

Get full text

Pathogenesis, clinical evolution and outcomes of patients with immune checkpoint inhibitor induced acute liver injury: A multicentre study by Au, L., Nathwani, R., Possamai, L., Barlow, C., Tillett, T., Bowen, R., Spain, L., Thomas, J., Backhouse, M., Gurung, A., Morrison, R., Cross, T., Herbert, C., Goldin, R., Gore, M.E., Larkin, J., Antoniades, C., Turajlic, S.

Get full text

Generalized melanosis and melanuria in a patient with metastatic melanoma by Perez, A., Turajlic, S., Szyszko, T., O'Doherty, M., Calonje, E., Harries, M., Acland, K.

Get full text

18ORepresentative sequencing: Profiling extreme tumor diversity by Litchfield, K, Swanton, C, Turajlic, S

Get full text